Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures

IMPORTANCE: Prescription drug spending in the US requires policy intervention to control costs and improve the value obtained from pharmaceutical spending. One such intervention is to apply cost-effectiveness evidence to decisions regarding drug coverage and pricing, but this intervention depends on...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Netw Open
Egile Nagusiak: Tisdale, Rebecca L., Ma, Iris, Vail, Daniel, Bhattacharya, Jay, Goldhaber-Fiebert, Jeremy D., Heidenreich, Paul A., Sandhu, Alexander T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2021
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8214163/
https://ncbi.nlm.nih.gov/pubmed/34143189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.13969
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak